In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/Onyx will wait for kidney oncologic Phase III data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Bayer/Onyx plan to wait for Phase III overall survival results for their kidney cancer agent BAY 43-9006 instead of moving forward with submission using Phase II data, which will push launch projections back to 2006. Bayer outlined a plan to file based on the Phase II results when the data was presented at the American Society of Clinical Oncology meeting in June. The firms expect to enroll 800 renal cell carcinoma patients in the Phase III trial of the RAF kinase inhibitor, now underway. The trial "was initiated after a special protocol assessment was completed by the FDA in the fourth quarter of 2003," Onyx says Oct. 25...

You may also be interested in...



Bayer/Onyx BAY 43-9006 Interim Analysis To Support Accelerated NDA Filing

Onyx expects its kidney cancer therapy BAY 43-9006 to receive accelerated approval by 2006 based on initial Phase III data showing statistically significantly longer progression-free survival versus placebo

Bayer/Onyx 43-9006 in Phase III for HCC

Bayer/Onyx are starting a Phase III study of their oral RAF kinase/VEGF inhibitor 43-9006 (sorafenib) for use as monotherapy in advanced hepatocellular carcinoma, the firms say March 8. Five hundred patients without prior systemic treatment will be randomized in the double-blind, placebo-controlled trial; overall survival, time to symptom progression and time to tumor progression will be assessed. Median survival was 9.2 months and median time to progression was 4.2 months in a Phase II HCC trial. Bayer/Onyx originally planned to submit 43-9006 for renal cell carcinoma based on Phase II data, but are now waiting for results from an 800-patient Phase III study (1Pharmaceutical Approvals Monthly November 2004, p. 35). Both Phase III trials received special protocol assessments from FDA...

UK Sunscreen Claims On ‘Negligible’ Difference In SPF Strengths Don't Add Up

Advertising Standards Authority says Green People Co. misled consumers with claims SPF 30 formulas filter out only 1% less UVB rays than SPF 50, trying to draw a negligible difference between the formulas. The claims appeared in a direct mailer and on the brand’s website in July 2019.

Topics

UsernamePublicRestriction

Register

PS002693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel